source
- Roivant's experimental pulmonary hypertension drug meets Phase 2 goalsRoivant announced that its experimental drug mosliciguat achieved the primary endpoint in a 16‑week Phase 2 trial for pulmonary hypertension, a serious lung condition. The study showed a 56% reduc…
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…